Related search

The ODYSSEY DM-DYSLIPIDEMIA Trial: Confirming the Benefits of Alirocumab in Diabetic Mixed Dyslipidemia

Annals of Translational Medicine
Medicine
2017English

Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India

Circulation
Cardiovascular MedicinePhysiologyCardiology
2009English

High Risk of Fatal and Nonfatal Venous Thromboembolism in Myotonic Dystrophy

Circulation
Cardiovascular MedicinePhysiologyCardiology
2018English

Declining Rates of Fatal and Nonfatal Intracerebral Hemorrhage: Epidemiological Trends in Australia

Journal of the American Heart Association
Cardiovascular MedicineCardiology
2014English

Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Independent of LDL Cholesterol and Statin Use: Results of the Leader Trial

Canadian Journal of Cardiology
Cardiovascular MedicineCardiology
2018English

Influence of Male and Female Educational Status on the Risk of Fatal Cardiovascular Events

Acta Biologica Sibirica
2015English

Nonfatal Outcomes in the Primary Prevention of Atherosclerotic Cardiovascular Disease: Is All-Cause Mortality Really All That Matters?

Circulation. Cardiovascular quality and outcomes
MedicineCardiovascular MedicineCardiology
2014English

Lipoprotein(a) Reductions From PCSK9 Inhibition and Major Adverse Cardiovascular Events: Pooled Analysis of Alirocumab Phase 3 Trials

Atherosclerosis
Cardiovascular MedicineCardiology
2019English

Tobacco Smoking and Risk of 36 Cardiovascular Disease Subtypes: Fatal and Non-Fatal Outcomes in a Large Prospective Australian Study

BMC Medicine
Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy